SavedAdd your journal

Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2012 / Cilt: 22 - Sayı: 1

Striking promotion of the in vitro myeloma monoclonal ımmunoglobulin aggregation by ankaferd hemostat

Ankaferd hemostat ileın vitro myelom monoklonalımmünglobulin agregasyonunun belirgin artışı

Harika ÇELEBİ
Aynur ALBAYRAK
Osman YOKUŞ
Server YAĞCI
Zeynep GİNİS
Özlem S. BALCIK
Murat ALBAYRAK
İbrahim C. HAZNEDAROĞLU
Salih AKSU
Pages
15–22
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

ÇELEBİ, H., ALBAYRAK, A., YOKUŞ, O., YAĞCI, S., GİNİS, Z., BALCIK, Ö. S., ALBAYRAK, M., HAZNEDAROĞLU, İ. C., AKSU, S. (2022). Striking promotion of the in vitro myeloma monoclonal ımmunoglobulin aggregation by ankaferd hemostat. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 22 - Sayı: 1, 15–22. https://ajindex.com/articles/644808

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Beyazit Y, Kurt M, Kekilli M, et al. Evaluation of hemos-tatic effects of Ankaferd as an alternative medicine. Al-tern Med Rev 15: 329-36, 2010
  2. Haznedaroglu BZ, Haznedaroglu IC, Walker SL, et al.Ultrastructural and morphological analyses of the invitro and in vivo hemostatic effects of Ankaferd BloodStopper. Clin Appl Thromb Hemost 16: 446-53, 2010
  3. Haznedaroglu IC. Molecular Basis of the PleiotropicEffects of Ankaferd Blood Stopper. IUBMB Life (Suppl)61: 290-290, 2009
  4. Ak G, Cakir O, Kazancioglu HO, et al. The use of anew hemostatic agent: Ankaferd Blood Stopper in he-mophiliacs. Haemophilia 16: 51-51, 2010
  5. Al B, Yildirim C, Cavdar M, et al. Effectiveness of An-kaferd blood stopper in the topical control of activebleeding due to cutaneous-subcutaneous incisions.Saudi Med J 30: 1520-1525, 2009
  6. Arslan S, Haznedaroglu IC, Oz B, et al. Endobronchialapplication of Ankaferd blood stopper to control profu-se lung bleeding leading to hypoxemia and hemody-namic instability. Resp Med CME 2: 144-146, 2009
  7. Balcik OS, Koroglu M, Cipil H, et al. A Placebo-Cont-rolled, Randomized, Double-Blinded, Cross-Over Pha-se I Clinical Study to Demonstrate Safety of AnkaferdBlood Stopper Topical Usage In Healthy Volunteers.Int J Lab Hem 32(Suppl 1):126-127, 2010
  8. Kurt M, Akdogan M, Onal IK, et al. Endoscopic topicalapplication of Ankaferd Blood Stopper for neoplasticgastrointestinal bleeding: A retrospective analysis. DigLiver Dis 42: 196-199, 2010
  9. Kurt M, Onal I, Akdogan M, et al. Ankaferd BloodStopper for controlling gastrointestinal bleeding due todistinct benign lesions refractory to conventional anti-hemorrhagic measures. Can J Gastroenterol 24: 380-384, 2010
  10. Meric Teker A, Korkut AY, Kahya V, et al. Prospective,randomized, controlled clinical trial of Ankaferd BloodStopper in patients with acute anterior epistaxis. EurArch Otorhinolaryngol 267: 1377-1381, 2010
  11. Teker AM, Korkut AY, Gedikli O, et al. Prospective,controlled clinical trial of Ankaferd Blood Stopper inchildren undergoing tonsillectomy. Int J Pediatr Otorhi-nolaryngol 73: 1742-1745, 2009
  12. Turhan N, Kurt M, Shorbagi A, et al. Topical AnkaferdBlood Stopper administration to bleeding gastrointes-tinal carcinomas decreases tumor vascularization. AmJ Gastroenterol 104: 2874-2877, 2009
  13. Yarali N, Oruc M, Bay A, et al. A new hemostaticagent-Ankaferd blood stopper: Management of gast-rointestinal bleeding in an infant and other experiencesin children. Pediatr Hematol Oncol